Imunon, Inc. (IMNN)

NASDAQ: IMNN · IEX Real-Time Price · USD
1.770
+0.370 (26.43%)
Mar 28, 2024, 11:33 AM EDT - Market open
26.43%
Market Cap 16.26M
Revenue (ttm) 125,000
Net Income (ttm) -27.86M
Shares Out 9.40M
EPS (ttm) -3.27
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 676,117
Open 1.520
Previous Close 1.400
Day's Range 1.401 - 1.885
52-Week Range 0.480 - 1.980
Beta 1.97
Analysts Strong Buy
Price Target 12.00 (+577.97%)
Earnings Date Mar 28, 2024

About IMNN

Imunon, Inc., a clinical stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The Company's lead clinical programs comprise IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development; and ThermoDox for the treatment of hepatocellular carcinoma. It also has two platform technologies, such as TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies; and PLA... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Mar 5, 1985
Employees 31
Stock Exchange NASDAQ
Ticker Symbol IMNN
Full Company Profile

Financial Performance

In 2022, Imunon's revenue was $500,000, a change of 0.00% compared to the previous year's $500,000. Losses were -$35.90 million, 72.8% more than in 2021.

Financial Statements

Analyst Forecast

According to one analyst, the rating for IMNN stock is "Strong Buy" and the 12-month stock price forecast is $12.0.

Price Target
$12.0
(577.97% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

IMUNON Reports 2023 Financial Results and Provides Business Update

Conference Call Begins Today at 10:00 a.m. Eastern Time LAWRENCEVILLE, N.J.

3 hours ago - GlobeNewsWire

IMUNON Receives $1.3 Million from Sale of its New Jersey Net Operating Losses

Non-dilutive funding strengthens balance sheet and extends current operating runway LAWRENCEVILLE, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a clinical-stage drug-developm...

3 days ago - GlobeNewsWire

IMUNON to Hold 2023 Financial Results and Business Update Conference Call on Thursday, March 28, 2024

LAWRENCEVILLE, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vac...

6 days ago - GlobeNewsWire

IMUNON Files IND Application to Begin Human Testing of IMNN-101

Company expects enrollment in Phase 1 proof-of-concept study of DNA-based vaccine technology to begin in Q2 The application follows guidance provided to IMUNON in Pre-IND meeting with the FDA

15 days ago - GlobeNewsWire

IMUNON Announces Leadership Change

Executive Chairman to lead day-to-day operations, active search underway for CEO successor.Timing of upcoming milestones for key programs remains unchanged.

15 days ago - GlobeNewsWire

Independent Lab Confirms Immunogenicity and Protection with IMUNON's IMNN-101 in a Live Virus Challenge Against SARS-CoV-2 Variant XBB.1.5

Murine Study by the Wistar Institute Builds Upon Favorable Results Previously Reported by IMUNON With its Prototype PlaCCine Vaccine Modality

4 weeks ago - GlobeNewsWire

Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON's IMNN-001 in Combination with Bevacizumab in Advanced Ovarian Cancer

Trial will evaluate the effect of this combination therapy on minimal residual disease LAWRENCEVILLE, N.J., Feb. 27, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-develop...

4 weeks ago - GlobeNewsWire

IMNN-101 Preclinical Data in SARS CoV-2 Published in Peer-Reviewed Journal Vaccine

Data Show Strong Immunogenicity and Protection with IMUNON's PlaCCine DNA-Based Vaccine Modality LAWRENCEVILLE, N.J., Feb. 22, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage dr...

5 weeks ago - GlobeNewsWire

IMUNON Appoints Dr. Sebastien Hazard as Chief Medical Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Accomplished pharmaceutical and biotechnology executive to lead IMUNON's clinical programs in ovarian cancer and infectious diseases

3 months ago - GlobeNewsWire

IMUNON's VP of R&D to Present at the Vaccines Summit-2023

Dr. Jean Boyer to highlight updated data showing the advantages of IMUNON's PlaCCine modality and its applicability to multiple pathogens

4 months ago - GlobeNewsWire

IMUNON Reports Third Quarter 2023 Financial Results and Provides a Business Update

Advances Non-Viral DNA-Mediated Cancer Immunotherapy and Next-Generation Vaccine Programs, with More Potent and Durable Immunity, with Multiple Near-Term Milestones

4 months ago - GlobeNewsWire

IMUNON to Hold Third Quarter 2023 Financial Results and Business Update Conference Call on Tuesday, November 14, 2023

LAWRENCEVILLE, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vacc...

5 months ago - GlobeNewsWire

IMUNON's Chief Science Officer to Present at the 3rd International Vaccines Congress

Highlights advantages of IMUNON's PlaCCine modality over current commercial vaccines LAWRENCEVILLE, N.J., Oct. 23, 2023 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a clinical-stage biotechnology...

5 months ago - GlobeNewsWire

IMUNON CEO Dr. Corinne Le Goff to Participate in a Panel Discussion on Pandemic Preparedness at the United Nations

“ A Tale of Two Pandemics: Lessons From the 1889 & 2019 Pandemics” presented by the Foreign Policy Association

5 months ago - GlobeNewsWire

IMUNON Announces First Patient enrolled in Phase 1/2 Clinical Trial of IMNN-001 in Combination with bevacizumab in Advanced Ovarian Cancer

The MRD trial will evaluate the effect of this treatment combination on minimal residual disease. LAWRENCEVILLE, N.J.

5 months ago - GlobeNewsWire

IMUNON Appoints Dr. Patrick Ott to its Scientific Advisory Board

Renowned Daner-Farber Cancer Institute researcher will advise on the development of IMUNON's FixPlas™ and Indiplas™ modalities in immuno-oncology.

6 months ago - GlobeNewsWire

IMUNON Reports Interim Progression-Free Survival and Overall Survival Data in Phase 1/2 OVATION 2 Study in Advanced Ovarian Cancer

Intent-to-treat population shows 9-month OS improvement over control arm Subgroup of patients treated with IMNN-001 + PARPi shows meaningful PFS and OS trend compared with control arm Continued follow...

6 months ago - GlobeNewsWire

IMUNON Releases Enterprise Video Highlighting the Company's Mission, Vision, Values, Breakthroughs and Technologies

Provides a look at the new manufacturing facility in Huntsville, Alabama Introduced as part of IMUNON's newly relaunched website LAWRENCEVILLE, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (N...

6 months ago - GlobeNewsWire

IMUNON Reminds Investors of its Virtual R&D Day Tomorrow at 4:00 p.m. ET

Program will feature executive management plus key opinion leaders in immuno-oncology and vaccine development LAWRENCEVILLE, N.J., Sept. 13, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN) , a cl...

7 months ago - GlobeNewsWire

IMUNON to Host Virtual R&D Day on September 14th Beginning at 4:00 p.m. ET

Program will feature members of IMUNON executive management along with key opinion leaders in immuno-oncology and vaccine development

7 months ago - GlobeNewsWire

IMUNON to Participate in the H.C. Wainwright Global Investment Conference

LAWRENCEVILLE, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage biotechnology company, announces that management will participate in the H.C. Wainwright 25th Annu...

7 months ago - GlobeNewsWire

IMUNON Enters into CRADA for Preclinical Studies of PlaCCine Modality in Preventive Vaccines Against Lassa Virus

CRADA will evaluate the immunogenicity and efficacy of two DNA-based Lassa virus vaccine candidate s in animal models

7 months ago - GlobeNewsWire

IMUNON Expands Scientific Advisory Board with the Addition of Dr. Sachet Shukla

Renowned scientist will advise on the development of IMUNON's FixPlas and IndiPlas modalities in immuno-oncology LAWRENCEVILLE, N.J., Aug. 14, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a c...

8 months ago - GlobeNewsWire

IMUNON Reports Second Quarter 2023 Financial Results and Provides Business Update

Advances Non-Viral DNA-Mediated Immunotherapy and Next-Generation Vaccine Programs with Multiple Near-Term Milestones Supported by a Strong Balance Sheet

8 months ago - GlobeNewsWire

Preclinical Data Showing Strong Immunogenicity and Protection with IMUNON's PlaCCine DNA-Based Vaccines Modality Available Online on bioRxiv

LAWRENCEVILLE, N.J., Aug. 07, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-genera...

8 months ago - GlobeNewsWire